ORIGINAL RESEARCH—ED PHARMACOTHERAPYEfficacy of Tadalafil in Men with Erectile Dysfunction Naïve to Phosphodiesterase 5 Inhibitor Therapy Compared with Prior Responders to Sildenafil Citrate
Introduction
Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor used for the treatment of erectile dysfunction (ED), defined as the persistent inability to achieve or maintain an erection sufficient for sexual activity [1]. In clinical trials, tadalafil improved erectile function in a broad population with mild to severe ED, as well as in various subpopulations (e.g., men with ED and diabetes mellitus) [2, 3, 4, 5, 6]. In these trials, nonresponders to prior sildenafil treatment, as identified by the investigators, were often excluded. This raised the possibility that the efficacy of tadalafil may have been elevated in the trials due to this exclusion, as the sildenafil nonresponders may also have been less likely to respond to tadalafil. This retrospective analysis explored this possibility by comparing the efficacy of tadalafil in patients with no history of PDE5 inhibitor therapy (naïve patients, presumably a mixture of potential responders and potential nonresponders) with that in patients who had responded to prior sildenafil treatment (prior responders).
Section snippets
Methods
In this retrospective analysis of pooled data from 14 double‐blind, placebo‐controlled, parallel‐group trials in the general ED population, the efficacy of tadalafil in 1,349 naïve patients was compared with that in 1,440 sildenafil prior responders. The trials were conducted worldwide at 184 sites in 23 countries between September 2000 and December 2003 (Table 1). The details of the general study design, efficacy, and safety measures were described in previous pooled data analyses of tadalafil
Study Population
Demographic and baseline characteristics were summarized for the naïve and prior‐responder groups, but no statistical comparisons were performed (Table 2). The percentage of patients with ED ≥1‐year duration ranged from 80% to 88% in the naïve‐patient groups treated with placebo, tadalafil 10 mg, and tadalafil 20 mg, and ranged from 92% to 96% in the prior‐responder groups. The percentage of patients with baseline IIEF‐EF scores that indicated severe ED ranged from 28% to 29% in the
Discussion
Tadalafil 10 mg and 20 mg significantly improved erectile function compared with placebo in both naïve and prior‐responder patients for all efficacy measures tested. For most of these efficacy measures, the responses of the naïve and prior‐responder patients were statistically similar. Thus, the results of this retrospective pooled data analysis suggest that the efficacy outcomes in clinical trials of tadalafil were not affected substantially by the exclusion of sildenafil nonresponders.
Conflict of Interest
Drs. Zhao, Sides, and Ahuja are employees of Eli Lilly and Co. Dr. Loughney is an employee of ICOS Corporation.
References (17)
- et al.
Summary of the recommendations on sexual dysfunctions in men
J Sex Med
(2004) - et al.
Efficacy and safety of tadalafil in the treatment of erectile dysfunction: Results of integrated analyses
J Urol
(2002) - et al.
The efficacy of tadalafil in clinical populations
J Sex Med
(2005) - et al.
Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: A randomized, double‐blind, placebo controlled trial
J Urol
(2004) - et al.
The International Index of Erectile Function (IIEF): A multidimensional scale for the assessment of erectile dysfunction
Urology
(1997) - et al.
Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment
J Urol
(1999) - et al.
Salvage of sildenafil failures referred from primary care physicians
J Urol
(2003) - et al.
Clinical efficacy of sildenafil citrate and predictors of long‐term response
J Urol
(2003)